To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
oral tablet
Vanda Investigational Site
Little Rock, Arkansas, United States
RECRUITINGVanda Investigational Site
Denver, Colorado, United States
RECRUITINGVanda Investigational Site
Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Atlanta, Georgia, United States
Vanda Investigational Site
Atlanta, Georgia, United States
RECRUITINGVanda Investigational Site
Decatur, Georgia, United States
RECRUITINGVanda Investigational Site
Cincinnati, Ohio, United States
RECRUITINGVanda Investigational Site
Garfield Heights, Ohio, United States
RECRUITINGVanda Investigational Site
Westlake, Ohio, United States
NOT_YET_RECRUITINGVanda Investigational Site
Everett, Washington, United States
RECRUITING